EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phase

Serge Ferrari, Lothar Seefried, Dénes Páll, Ombretta Viapiana, Jan Rosa, Jerzy Supronik, Rodina Nestorova Licheva, Joachim Kiefer, Norbert Jeszenői, Károly Horvát-Karajz, Enikő Jókai, István Takács

Osteoporosis International · 2026

DOI: 10.1007/s00198-026-07964-0 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Osteoporosis International, 2026. Verfasst von Serge Ferrari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Bone Diseases, Geneva University Hospital, Geneva, Switzerland. Hauptthemen laut MEDLINE: Denosumab, Osteoporosis, Postmenopausal, Biosimilar Pharmaceuticals, Bone Density Conservation Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gedeon Richter.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoporosis is a chronic condition requiring long-term management of fracture risk. Biosimilars provide the possibility of continuous use of well-established compounds. Proposed denosumab biosimilar RGB-14-P demonstrated equivalent efficacy and similar pharmacodynamics, immunogenicity, and safety to the reference denosumab. Transitioning from reference denosumab to RGB-14-P was associated with continued effectiveness and safety. PURPOSE: To establish the therapeutic equivalence of RGB-14-P and reference denosumab (RD) in postmenopausal women with osteoporosis through demonstrating equivalent efficacy and similar safety, pharmacodynamics (PD), and immunogenicity when transitioning from RD to RGB-14-P. METHODS: Patients (n = 188) who had received two 60-mg doses of RGB-14-P or RD (day 1 and week 26) in a randomised, blinded, controlled phase 3 study were re-randomised 1:1:1 at week 52 to continue RGB-14-P (n = 63) or RD (n = 63) or transition from RD to RGB-14-P (n = 62) and followed to week 78. RESULTS: Gains in lumbar spine, hip, and femoral neck bone mineral density (BMD) observed in the first 52 weeks of treatment were further improved up to week 78 in all three groups, including patients who transitioned from RD to RGB-14-P. Incidences of new fragility fractures were comparable. Changes from baseline in serum PD markers (serum C-telopeptide of type I collagen and procollagen type I N-terminal propeptide) were maintained. The transition did not induce a discernible immunological reaction, and there were no clinically meaningful between-group differences in safety. CONCLUSION: Treatment responses to RGB-14-P or RD seen during the first 52 weeks of treatment further improved to week 78; transitioning from RD to RGB-14-P had no discernible impact on efficacy, PD, immunogenicity, or safety. The totality of the evidence on the proposed biosimilar RGB-14-P available to date demonstrated structural and functional similarity as well as PK, PD, and therapeutic equivalence to reference denosumab, which suggests that RGB-14-P can be considered for long-term treatment, as well as a continuation of denosumab treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabOsteoporosis, PostmenopausalBiosimilar PharmaceuticalsBone Density Conservation AgentsHumansFemaleAgedBone DensityMiddle AgedTherapeutic EquivalencyDrug Administration ScheduleTreatment OutcomeDrug SubstitutionLumbar VertebraeDouble-Blind MethodFemur NeckBiomarkersOsteoporotic FracturesHip Joint

Stichwörter der Autor:innen

BiosimilarDenosumabInterchangeabilityPostmenopausal osteoporosisRGB-14-PRandomised controlled trial

Substanzen

DenosumabBiosimilar PharmaceuticalsBone Density Conservation AgentsBiomarkers

Autor:innen und Institutionen

  • Division of Bone Diseases, Geneva University Hospital, Geneva, Switzerland.
  • Musculoskeletal Center Würzburg, University of Würzburg, Würzburg, Germany.
  • Department of Medical Clinical Pharmacology, University of Debrecen, Debrecen, Hungary.
  • Department of Medicine, Rheumatology Unit, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • Osteoporosis and Metabolic Bone Disease Center Affidea, Prague, Czech Republic.
  • NZOZ Centrum Medyczne Artur Racewicz, Białystok, Poland.

Förderung

  • Gedeon Richter

Zitieren

APA

Ferrari, S., Seefried, L., Páll, D., Viapiana, O., Rosa, J., Supronik, J., Nestorova Licheva, R., Kiefer, J., Jeszenői, N., Horvát-Karajz, K., Jókai, E., & Takács, I. (2026). Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phase. Osteoporosis International. https://doi.org/10.1007/s00198-026-07964-0

Vancouver

Ferrari S, Seefried L, Páll D, Viapiana O, Rosa J, Supronik J, et al. Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phase. Osteoporosis International. 2026. doi:10.1007/s00198-026-07964-0

BibTeX
@article{Ferrari2026,
  author = {Ferrari, Serge and Seefried, Lothar and Páll, Dénes and Viapiana, Ombretta and Rosa, Jan and Supronik, Jerzy and Nestorova Licheva, Rodina and Kiefer, Joachim and Jeszenői, Norbert and Horvát-Karajz, Károly and Jókai, Enikő and Takács, István},
  title = {Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phase},
  journal = {Osteoporosis International},
  year = {2026},
  doi = {10.1007/s00198-026-07964-0}
}
Kostenlos starten →